Landos Biopharma, Inc. (NASDAQ:LABP) Short Interest Update

Landos Biopharma, Inc. (NASDAQ:LABP - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 4,900 shares, an increase of 345.5% from the March 15th total of 1,100 shares. Based on an average daily trading volume, of 23,300 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "neutral" rating and set a $20.42 price target (down previously from $50.00) on shares of Landos Biopharma in a research note on Monday, April 1st.

Hedge Funds Weigh In On Landos Biopharma

Several hedge funds have recently modified their holdings of LABP. HRT Financial LP bought a new stake in Landos Biopharma in the 4th quarter valued at $26,000. Vanguard Group Inc. grew its position in shares of Landos Biopharma by 30.6% during the third quarter. Vanguard Group Inc. now owns 166,608 shares of the company's stock valued at $108,000 after purchasing an additional 39,053 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Landos Biopharma by 119.1% in the second quarter. Goldman Sachs Group Inc. now owns 42,800 shares of the company's stock worth $31,000 after purchasing an additional 23,263 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Landos Biopharma by 14.2% in the second quarter. Renaissance Technologies LLC now owns 388,732 shares of the company's stock worth $283,000 after buying an additional 48,232 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Landos Biopharma by 80.4% during the first quarter. Bank of America Corp DE now owns 56,321 shares of the company's stock valued at $83,000 after buying an additional 25,096 shares during the last quarter. Hedge funds and other institutional investors own 49.06% of the company's stock.

Landos Biopharma Stock Up 0.3 %

LABP traded up $0.05 on Wednesday, hitting $21.56. 31,043 shares of the company's stock traded hands, compared to its average volume of 22,980. Landos Biopharma has a one year low of $2.50 and a one year high of $21.87. The company's 50 day simple moving average is $9.78 and its 200-day simple moving average is $6.09.

About Landos Biopharma

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.